Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-6.01 | N/A | -256.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-6.01 | N/A | -256.47% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the recent financial performance, particularly the EPS results. They remain focused on navigating the company's challenges while aiming for future growth.
Management acknowledged the significant EPS loss and emphasized ongoing challenges.
They reiterated their commitment to long-term goals despite current setbacks.
Disc Medicine Inc reported a significant EPS loss, which was not unexpected given the lack of consensus estimates. Despite this, the stock rose by 1.52%, indicating that investors may have anticipated worse results or are optimistic about future prospects. The absence of revenue data and guidance adds uncertainty to the outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Feb 23, 2026